Guardant Health , a global leader in precision oncology, has entered into a strategic partnership with Zephyr AI, a pioneer in applying artificial intelligence to accelerate precision medicine and drug development. The collaboration aims to unlock new, scalable, and actionable insights that drive innovation across biopharmaceutical research, biomarker discovery, and precision cancer therapies.
By integrating the partnership within Guardant’s Infinity AI ecosystem, the two companies reinforce their shared vision of leveraging AI and multimodal data to empower oncologists, researchers, and biopharma developers with transformative tools to enhance cancer care and outcomes.
“At Guardant Health, we’ve always believed that data is key to conquering cancer,” said Helmy Eltoukhy, chairman and co-CEO of Guardant Health. “By combining our industry-leading molecular data with Zephyr AI’s advanced analytics platform, we’re taking another major step toward realizing the full potential of precision oncology—helping our biopharma partners accelerate drug development and ultimately deliver better outcomes for patients worldwide.”
This collaboration merges Guardant’s multimodal real-world molecular data and precision oncology insights with Zephyr AI’s proprietary AI and machine learning technologies. The partnership’s strength lies in its ability to generate predictive models of targeted cancer therapy response—validated by real-world data—while maintaining biological interpretability to ensure actionable scientific intelligence.
“This collaboration represents the convergence of unmatched real-world data, leading-edge diagnostics and cutting-edge machine learning to enable more precise, scalable, and impactful oncology solutions,” said Allen Chao, CEO of Zephyr AI. “By working together, Guardant Health and Zephyr AI can supercharge discovery and development needed to transform cancer treatment and deliver on the promise of personalized medicines for cancer patients.”
Also Read